NASDAQ:SEEL Seelos Therapeutics (SEEL) Stock Price, News & Analysis → He Is Giving Away Bitcoin (From Crypto Swap Profits) (Ad) Free SEEL Stock Alerts $0.31 -0.02 (-6.02%) (As of 12:46 PM ET) Add Compare Share Share Today's Range$0.29▼$0.3350-Day Range$0.33▼$1.2952-Week Range$0.29▼$49.80Volume463,781 shsAverage Volume426,966 shsMarket Capitalization$4.21 millionP/E RatioN/ADividend YieldN/APrice Target$70.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Seelos Therapeutics alerts: Email Address Seelos Therapeutics MarketRank™ Stock AnalysisAnalyst RatingHold2.33 Rating ScoreUpside/Downside21,300.2% Upside$70.00 Price TargetShort InterestHealthy5.82% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.91 out of 5 stars 3.2 Analyst's Opinion Consensus RatingSeelos Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 1 buy rating, 2 hold ratings, and no sell ratings.Amount of Analyst CoverageSeelos Therapeutics has received no research coverage in the past 90 days. Previous Next 4.0 Short Interest Percentage of Shares Shorted5.82% of the float of Seelos Therapeutics has been sold short.Short Interest Ratio / Days to CoverSeelos Therapeutics has a short interest ratio ("days to cover") of 1.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Seelos Therapeutics has recently decreased by 10.82%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldSeelos Therapeutics does not currently pay a dividend.Dividend GrowthSeelos Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for SEEL. Previous Next 0.6 News and Social Media Coverage Search InterestOnly 9 people have searched for SEEL on MarketBeat in the last 30 days. This is a decrease of -25% compared to the previous 30 days.MarketBeat Follows2 people have added Seelos Therapeutics to their MarketBeat watchlist in the last 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Seelos Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 5.40% of the stock of Seelos Therapeutics is held by insiders.Percentage Held by InstitutionsOnly 23.37% of the stock of Seelos Therapeutics is held by institutions. Previous Next N/A Earnings and Valuation Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto Swap ProfitsHe Is Giving Away BitcoinAnd my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.>> Register right here About Seelos Therapeutics Stock (NASDAQ:SEEL)Seelos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of central nervous system, respiratory, and other disorders. The company's lead programs are SLS-002, an intranasal racemic ketamine for the treatment of acute suicidal ideation and behavior in patients with major depressive disorders; SLS-005, a protein stabilizer for the treatment of amyotrophic lateral sclerosis and Sanfilippo syndrome; and SLS-006, a partial dopamine agonist for the treatment of patients with Parkinson's disease (PD). Its preclinical programs include SLS-007, a peptidic inhibitor to treat patients with PD; SLS-008 for the treatment of pediatric indications; SLS-004 for the treatment of PD; SLS-010, an H3 receptor antagonist; and SLS-012. The company was founded in 2016 and is headquartered in New York, New York.Read More SEEL Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart SEEL Stock News HeadlinesMarch 22, 2024 | investorplace.comSEEL Stock Earnings: Seelos Therapeutics Beats EPS for Q4 2023March 20, 2024 | markets.businessinsider.comOptimistic Buy Rating for Seelos Therapeutics Amid Promising Drug Trial ResultsApril 24, 2024 | WealthPress (Ad)$25,000 into $109,616 in two months? Today I want to show you how our research shows you could’ve grown a $25,000 account into $109,616.12 within the last TWO months. You see, former multi-million dollar hedge fund manager Roger Scott spent the better half of 2023 developing what might be the most advanced trading tool that exists… It’s a revolutionary software system that tracks the moves of institutional investors…. in real time…March 19, 2024 | markets.businessinsider.comSeelos: Phase 2/3 HEALEY ALS Trial Fails To Meet Statistical Significance In EndpointsMarch 19, 2024 | marketwatch.comSeelos Therapeutics Shares Drop 47% After SLS-005 Trial Misses Primary EndpointsMarch 19, 2024 | markets.businessinsider.comNasdaq Down 100 Points; US Housing Starts Surge In FebruaryMarch 19, 2024 | msn.comCNS Disorder-Focused Seelos Therapeutics Plunges To 52-Week Low - Here's WhyMarch 19, 2024 | reuters.comSeelos says ALS treatment fails in mid-stage studyApril 24, 2024 | WealthPress (Ad)$25,000 into $109,616 in two months? Today I want to show you how our research shows you could’ve grown a $25,000 account into $109,616.12 within the last TWO months. You see, former multi-million dollar hedge fund manager Roger Scott spent the better half of 2023 developing what might be the most advanced trading tool that exists… It’s a revolutionary software system that tracks the moves of institutional investors…. in real time…March 19, 2024 | finance.yahoo.comUPDATE 2-Seelos Therapeutics' ALS treatment fails mid-stage studyMarch 19, 2024 | msn.comSeelos falls as lead drug fails in ALS trialMarch 19, 2024 | prnewswire.comSeelos Therapeutics Provides Update on Top-Line Results from its Amyotrophic Lateral Sclerosis (ALS) Study with SLS-005 (IV Trehalose)February 9, 2024 | thestreet.comSeelos Therapeutics Inc.February 1, 2024 | ca.finance.yahoo.comSeelos Therapeutics, Inc. (SEEL)January 31, 2024 | msn.comSeelos Therapeutics Issues Common Warrants to InvestorsJanuary 31, 2024 | msn.comSeelos Therapeutics Strikes $4M Direct Offering DealJanuary 26, 2024 | markets.businessinsider.comSeelos Therapeutics Announces $4 Mln Direct Offering And Private Placement Of SharesJanuary 26, 2024 | marketwatch.comSeelos Therapeutics Shares Hit 52-Week Low After Direct Offering PricesJanuary 26, 2024 | finance.yahoo.comSeelos Therapeutics, Inc. Announces $4.0 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq RulesJanuary 22, 2024 | markets.businessinsider.comSeelos Therapeutics Says Received Minutes From End Of Phase II Meeting With FDAJanuary 22, 2024 | finance.yahoo.comSeelos Therapeutics Announces Receipt of Minutes from its End of Phase II Meeting with the United States Food and Drug Administration (FDA) Highlighting Modifications to the Primary and Secondary Endpoints of its Phase II Study of SLS-002January 17, 2024 | finance.yahoo.comTherapy’s New Frontier: 3 Psychedelic Stocks for the Mental Health RevolutionJanuary 16, 2024 | finance.yahoo.comSeelos Therapeutics, Inc. (SEEL) stock forecast and price targetJanuary 5, 2024 | morningstar.comSeelos Therapeutics Inc SEELJanuary 2, 2024 | markets.businessinsider.comSeelos Therapeutics: ISS Recommends Stockholders Vote For All Proposals - Quick FactsJanuary 2, 2024 | finance.yahoo.comLeading Independent Proxy Advisory Firm ISS Recommends Seelos Stockholders Vote "FOR" All Proxy Proposals at the Special Meeting to be held on January 10, 2024December 22, 2023 | finance.yahoo.comSeelos Therapeutics, Inc. Releases Letter to its StockholdersSee More Headlines Receive SEEL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Seelos Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today4/24/2024Next Earnings (Estimated)5/20/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:SEEL CUSIPN/A CIK1017491 Webwww.seelostherapeutics.com Phone(646) 293-2100Fax858-436-8155Employees15Year Founded2016Price Target and Rating Average Stock Price Target$70.00 High Stock Price Target$120.00 Low Stock Price Target$30.00 Potential Upside/Downside+22,671.6%Consensus RatingHold Rating Score (0-4)2.33 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-37,880,000.00 Net Margins-1,719.56% Pretax Margin-1,719.56% Return on EquityN/A Return on Assets-517.23% Debt Debt-to-Equity RatioN/A Current Ratio0.14 Quick Ratio0.14 Sales & Book Value Annual Sales$2.20 million Price / Sales1.91 Cash FlowN/A Price / Cash FlowN/A Book Value($3.42) per share Price / Book-0.09Miscellaneous Outstanding Shares13,680,000Free Float12,942,000Market Cap$4.21 million OptionableOptionable Beta1.88 Social Links Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report Key ExecutivesDr. Raj Mehra J.D. (Age 63)Ph.D., Founder, Chairman, CEO & President Comp: $599.53kMr. Michael J. Golembiewski (Age 52)Chief Financial Officer Comp: $388.2kMs. Kimberly FarrandSenior Director of Clinical Development & OperationsMr. Anthony MarcianoChief Communications OfficerGopal Krishna Ph.D.Head of Manufacturing & Technical OperationsTim Whitaker M.D.Chief Medical OfficerMs. Karen FusaroSenior VP & Head of Clinical OperationsMore ExecutivesKey CompetitorsTharimmuneNASDAQ:THARGenprexNASDAQ:GNPXChina PharmaNYSE:CPHICingulateNASDAQ:CINGLipella PharmaceuticalsNASDAQ:LIPOView All CompetitorsInstitutional OwnershipWealth Effects LLCBought 238,067 shares on 4/23/2024Ownership: 3.411%Gendell Jeffrey LSold 6,632,970 shares on 2/15/2024Ownership: 1.514%Modera Wealth Management LLCSold 1,154,048 shares on 2/15/2024Ownership: 0.946%AdvisorShares Investments LLCSold 440,058 shares on 2/14/2024Ownership: 2.459%Wealth Effects LLCSold 3,376,653 shares on 1/29/2024Ownership: 3.102%View All Institutional Transactions SEEL Stock Analysis - Frequently Asked Questions Should I buy or sell Seelos Therapeutics stock right now? 3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Seelos Therapeutics in the last twelve months. There are currently 2 hold ratings and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" SEEL shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in SEEL, but not buy additional shares or sell existing shares. View SEEL analyst ratings or view top-rated stocks. What is Seelos Therapeutics' stock price target for 2024? 3 Wall Street analysts have issued twelve-month target prices for Seelos Therapeutics' stock. Their SEEL share price targets range from $30.00 to $120.00. On average, they expect the company's stock price to reach $70.00 in the next year. This suggests a possible upside of 21,300.2% from the stock's current price. View analysts price targets for SEEL or view top-rated stocks among Wall Street analysts. How have SEEL shares performed in 2024? Seelos Therapeutics' stock was trading at $1.39 at the start of the year. Since then, SEEL stock has decreased by 76.5% and is now trading at $0.3271. View the best growth stocks for 2024 here. When is Seelos Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024. View our SEEL earnings forecast. What ETF holds Seelos Therapeutics' stock? AdvisorShares Psychedelics ETF holds 513,330 shares of SEEL stock, representing 3.32% of its portfolio. When did Seelos Therapeutics' stock split? Seelos Therapeutics shares reverse split on the morning of Tuesday, November 28th 2023. The 1-30 reverse split was announced on Tuesday, November 28th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, November 28th 2023. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split. What other stocks do shareholders of Seelos Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Seelos Therapeutics investors own include VBI Vaccines (VBIV), Sorrento Therapeutics (SRNE), Tonix Pharmaceuticals (TNXP), Vaxart (VXRT), Biocept (BIOC), Onconova Therapeutics (ONTX), Co-Diagnostics (CODX), Heat Biologics (HTBX), iBio (IBIO) and OPKO Health (OPK). Who are Seelos Therapeutics' major shareholders? Seelos Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Wealth Effects LLC (3.41%). Insiders that own company stock include Daniel J O'connor and Raj Mehra. View institutional ownership trends. How do I buy shares of Seelos Therapeutics? Shares of SEEL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:SEEL) was last updated on 4/24/2024 by MarketBeat.com Staff From Our Partnerstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyThis Apple-like Innovator is Revolutionizing HealthcareWall Street StarDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsBitcoin Rockets To Record High But Buy THIS InsteadParadigm PressThe #1 Crypto for 2024InvestorPlaceEmergency: Biden's $20 Trillion Mistake Could Cost YOU!GoldenCrest MetalsDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill PublishingThe Greatest Bull Market in Crypto History…Weiss Ratings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Seelos Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
